Findings
Limited awareness and clarity regarding the qualification process and evidentiary expectations.
High resource and data demands for robust qualification submissions, particularly for novel DDTs.
Challenges in integrating multidisciplinary expertise to develop and validate DDTs.
Dependence on effective collaboration among stakeholders, including academia, industry, and regulatory bodies.
Potential delays in submission reviews if deficiencies are identified during initial assessments.

Recommendations
Define a clear and scientifically robust Context of Use (COU) for each DDT to streamline the qualification process.
Engage with FDA through early meetings to align on submission expectations and address potential gaps.
Leverage biomedical consortia and partnerships to pool resources and expertise for DDT development and validation.
Provide detailed study protocols, data analyses, and evidence in submissions to support DDT reliability and applicability.
Utilize FDA’s NextGen Portal for submission tracking and ensure compliance with recommended data standards.

Regulatory Considerations
Compliance with the three-stage qualification process: Letter of Intent (LOI), Qualification Plan (QP), and Full Qualification Package (FQP).
Adherence to transparency provisions under the 21st Century Cures Act, including public disclosure of qualification information and Determination Letters.
Rescission or modification of a qualified DDT or COU if new evidence challenges its validity.
Clear distinction between qualification for regulatory decision-making and approval for clinical use or marketing.
Encouragement to use study data standards (e.g., Clinical Data Interchange Standards Consortium) for submissions to ensure consistency and quality.